Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) has received a consensus recommendation of "Buy" from the eleven analysts that are currently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $20.13.
Several research firms have weighed in on LRMR. Truist Financial began coverage on Larimar Therapeutics in a research report on Wednesday, January 29th. They set a "buy" rating and a $18.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Larimar Therapeutics in a research report on Friday, January 24th. Finally, William Blair reaffirmed an "outperform" rating on shares of Larimar Therapeutics in a research report on Tuesday, November 19th.
Get Our Latest Stock Report on LRMR
Larimar Therapeutics Trading Up 3.8 %
Shares of NASDAQ:LRMR traded up $0.11 during trading on Wednesday, hitting $3.03. 365,276 shares of the company were exchanged, compared to its average volume of 554,220. The stock has a market cap of $193.34 million, a price-to-earnings ratio of -2.63 and a beta of 0.91. Larimar Therapeutics has a fifty-two week low of $2.86 and a fifty-two week high of $11.97. The firm has a fifty day moving average price of $3.54 and a two-hundred day moving average price of $5.85.
Institutional Trading of Larimar Therapeutics
Several institutional investors have recently added to or reduced their stakes in LRMR. BNP Paribas Financial Markets bought a new stake in Larimar Therapeutics in the 4th quarter valued at $25,000. Algert Global LLC bought a new stake in Larimar Therapeutics in the 4th quarter valued at $47,000. China Universal Asset Management Co. Ltd. bought a new stake in Larimar Therapeutics in the 4th quarter valued at $52,000. Graham Capital Management L.P. bought a new stake in Larimar Therapeutics in the 4th quarter valued at $54,000. Finally, ProShare Advisors LLC bought a new stake in Larimar Therapeutics in the 4th quarter valued at $58,000. 91.92% of the stock is currently owned by institutional investors.
Larimar Therapeutics Company Profile
(
Get Free ReportLarimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
Further Reading
Before you consider Larimar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.
While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
